Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CSBR 
Champions Oncology Inc (CSBR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CSBR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.43% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 107.30M USD | Price to earnings Ratio 17.24 | 1Y Target Price 12 |
Price to earnings Ratio 17.24 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.37 | 52 Weeks Range 3.60 - 11.99 | Updated Date 06/29/2025 |
52 Weeks Range 3.60 - 11.99 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.97% | Operating Margin (TTM) 26.4% |
Management Effectiveness
Return on Assets (TTM) 14.64% | Return on Equity (TTM) 37.68% |
Valuation
Trailing PE 17.24 | Forward PE 22.88 | Enterprise Value 108596008 | Price to Sales(TTM) 1.83 |
Enterprise Value 108596008 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA 12.89 | Shares Outstanding 13826900 | Shares Floating 5118582 |
Shares Outstanding 13826900 | Shares Floating 5118582 | ||
Percent Insiders 25.85 | Percent Institutions 49.3 |
Analyst Ratings
Rating 1 | Target Price 12 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Champions Oncology Inc
Company Overview
History and Background
Champions Oncology, Inc. was founded in 2007. It focuses on developing advanced technology solutions and services to personalize and improve the development and use of oncology drugs. The company has grown through organic development and acquisitions, expanding its offerings in precision oncology.
Core Business Areas
- Personalized Oncology Solutions: Provides in vivo, ex vivo and in vitro services using patient-derived xenograft (PDX) models, cell line panels, and other assays to assess drug efficacy and mechanisms of action.
- Translational Oncology Solutions: Offers a suite of services including biomarker analysis, genomics, and proteomics to advance drug development and understand tumor biology.
- Data and Analytics Solutions: Provides access to a proprietary database of PDX models and associated data, enabling researchers to identify promising drug candidates and predict patient response.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives overseeing different business units. The organizational structure is typically functional, with departments dedicated to R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- PDX Models: Patient-Derived Xenograft models are Champions Oncology's core product, providing preclinical platforms for drug testing and development. While precise market share data is difficult to obtain, Champions Oncology is a significant player in this space. Competitors include Charles River Laboratories (CRL) and The Jackson Laboratory.
- TumorGraft Bank: A collection of over 800 highly characterized patient-derived xenograft (PDX) models representing more than 25 different tumor types. Revenue generated from access to this bank is significant. Competitors include Wuxi AppTec and Crown Bioscience.
- Champions TumorGraft: PDX model development and testing services. No exact number available. Competitors are Charles River and JAX.
Market Dynamics
Industry Overview
The precision oncology industry is experiencing rapid growth, driven by advancements in genomics and personalized medicine. There's increasing demand for preclinical models and data-driven insights to improve drug development success rates.
Positioning
Champions Oncology is positioned as a leading provider of PDX models and related services, offering comprehensive solutions for drug discovery and development. Their competitive advantage lies in their extensive PDX library and expertise in translational oncology.
Total Addressable Market (TAM)
The TAM for preclinical oncology models and services is estimated to be in the billions of dollars. Champions Oncology is positioned to capture a significant portion of this market by providing advanced, data-rich solutions.
Upturn SWOT Analysis
Strengths
- Extensive PDX model library
- Strong expertise in translational oncology
- Proprietary data and analytics platform
- Established relationships with pharmaceutical companies
Weaknesses
- Reliance on preclinical models, which may not always translate to clinical success
- High cost of PDX model development and maintenance
- Dependence on research funding and pharmaceutical R&D budgets
Opportunities
- Expanding into new therapeutic areas, such as immuno-oncology
- Developing new PDX models that better reflect patient heterogeneity
- Leveraging artificial intelligence to improve drug prediction and patient selection
- Offering companion diagnostics to guide treatment decisions
Threats
- Competition from other PDX model providers and CROs
- Changes in regulatory requirements for drug development
- Economic downturns that reduce pharmaceutical R&D spending
- Advancements in alternative preclinical models, such as organoids
Competitors and Market Share
Key Competitors
- CRL
- Wuxi AppTec
- Crown Bioscience
Competitive Landscape
Champions Oncology competes with other PDX model providers and CROs. They differentiate themselves through their extensive PDX library, data-driven approach, and expertise in translational oncology. Charles River Labs has a larger financial footprint and may have deeper relationships.
Growth Trajectory and Initiatives
Historical Growth: Champions Oncology's historical growth has been driven by increasing demand for its PDX models and related services. The company has also expanded through acquisitions and strategic partnerships.
Future Projections: Analysts project continued growth for Champions Oncology, driven by advancements in precision oncology and the increasing need for predictive preclinical models.
Recent Initiatives: Recent initiatives include expanding the PDX model library, developing new data and analytics tools, and strengthening partnerships with pharmaceutical companies.
Summary
Champions Oncology is a key player in the precision oncology market, with strengths in PDX models and translational oncology. They are positioned to capitalize on industry growth, but face competition from larger CROs and reliance on pharmaceutical R&D spending. The company should explore new therapeutic areas and emerging technologies to maintain its competitive edge and enhance drug prediction capabilities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Estimates
- Public Filings
Disclaimers:
This analysis is based on publicly available information and analyst estimates, and should not be considered financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Champions Oncology Inc
Exchange NASDAQ | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 2003-01-10 | CEO & Director Dr. Ronnie Morris M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 210 | |
Full time employees 210 | |||
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.